Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

A Phase III Double-blind, Randomized, Parallel Group, Multicenter Placebo-controlled Trial to Study the Efficacy and Safety of Caplacizumab in Patients With Acquired Thrombotic Thrombocytopenic Purpura

Next Previous
Trial Profile

A Phase III Double-blind, Randomized, Parallel Group, Multicenter Placebo-controlled Trial to Study the Efficacy and Safety of Caplacizumab in Patients With Acquired Thrombotic Thrombocytopenic Purpura

Status: Completed
Phase of Trial: Phase III

Latest Information Update: 24 Jan 2024

Price :
$35 *
Note:
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs Caplacizumab (Primary) ; Caplacizumab (Primary) ; Corticosteroids; Cyclophosphamide; Hydroxychloroquine; Mycophenolate mofetil; Rituximab
  • Indications Thrombosis; Thrombotic thrombocytopenic purpura
  • Focus Registrational; Therapeutic Use
  • Acronyms HERCULES
  • Sponsors Ablynx

Most Recent Events

  • 12 Dec 2023 Results presented at the 65th American Society of Hematology Annual Meeting and Exposition
  • 13 Dec 2022 Results of post hoc analysis (from two studies HERCULES and post-HERCULES) assessing the efficacy and safety of caplacizumab in patients with iTTP presented at the 64th American Society of Hematology Annual Meeting and Exposition
  • 14 Dec 2021 Results from TITAN, HERCULES and other studies, comparing patient-centered outcomes from Germany and Austria, presented at the 63rd American Society of Hematology Annual Meeting and Exposition

You need to be a logged in or subscribed to view this content

Request demo (opens in a new window)
If your organization or you do not have a subscription, try one of the following: If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top